ClinicalTrials.gg
CompletedNCT03332719GEMENEUpdated Nov 6, 2017

Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis

A Phase 3 interventional study of Etanercept and Methotrexate in Rheumatoid Arthritis, sponsored by Gema Biotech S.A.. Completed at 1 site in Argentina. Open to participants aged 19 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-11-06.

Sponsored by Gema Biotech S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
19 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
49th of 113
168 · median 130
Started
2016
with 5 others
Phase 3
47 of 113
1 open now
Registered
90th of 113
by date

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 49th largest by enrollment, is one of 6 that started in 2016, is one of 47 in phase 3, and was the 90th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 19 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to asses the compared efficacy, safety and immunogenicity of ENERCEPTAN® with ENBREL® in combination with Methotrexate for the treatment of patients with rheumatoid arthritis.

Read the detailed description

Randomized, , non-inferiority, two parallel arms, 32 weeks, blind for the assessor.

Subjects should be with inadequate response to methotrexate with stable dosis ≥ 15 and ≤ 25 mg/week 28 days before randomization.

Randomization will be 2:1 Enerceptan® to Enbrel® with concomitant medication of MTX

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
19 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult men and women over 18 years, who present moderate to severe active RA (rheumatoid arthritis) , diagnosed according to ACR/ EULAR 2010 criteria, who have failed prior MTX (methotrexate) therapy. Functional class I to III.
  2. Moderate to severe disease activity, according to DAS28 (erythrosedimentation) ≥ 3.2.
  3. Must have at least a minimum of 6 tender joints and 8 swollen joints. If a patient has a joint surgery prior to the study, this joint is considered not evaluable throughout the study development.
  4. Must have at least, one erosion in the baseline radiograph. Local assessment centers either radiologist or rheumatologist to decide on this criterion will be accepted.
  5. Medical Indication to incorporate a biological treatment in their therapy.
  6. Treatment with MTX for at least 3 months on dose ≥15 mg/ week, stable over the last 28 days before the Day 1. Doses lower than 15 mg and greater or equal than 10 mg/ week are accepted in cases with previously documented intolerance.
  7. Subjects who have previously received treatment with a biologic (approved or ) except etanercept, may participate as long as the corresponding washout time has elapsed prior to the screening interview: At least

    1. 8 weeks for infliximab (T1/2 8 to 9.5 days) and for tocilizumab (T1/2 3to 12 days)
    2. 10 weeks for adalimumab (T1/2 10 to 20 days), Golimumab (T1/2 11 to 14 days), certolizumab (T1/2 14 days), abatacept (T1/2 14 days),
    3. 1 year for Rituximab (T1/2 77,5 days)
    4. 5 T1/2 for any other biological product, used for the treatment of rheumatoid arthritis, wether it has been used or not for research.
    5. Subjects who are receiving leflunomide must have a previous of 8 weeks before Day 1, except had have treatment with colestyramine, according to manufacturer indications.
    6. Can receive non steroidal anti inflammatory drugs (NSAIDs) or oral corticoids in doses \< 10 mg of prednisone, but treatment must have been stable over the last 28 days.

      8 Subjects must be able to self-inject or willing to have a previously assigned caregiver do it for them.

      9 Subjects must be able to meet the schedule of visits, understand and comply with other protocol requirements.

      10 Women of childbearing age must commit to be using an adequate method of to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of Enbrel®/Enerceptan®. Suitable methods of contraception are oral contraceptives, IUDs (intrauterine device) , bilateral tubal ligation, vasectomy or double barrier methods such as condoms or spermicidal diaphragm, sponge, contraceptive foam or gel, heterosexual abstinence. Men should not conceive up to 12 weeks after stopping the MTX

      11 must be signed before making any study-specific procedure.

Exclusion criteria

Exclusion Criteria:

  1. Simultaneous treatment with other drug or participation in another clinical study that the investigator considers inadvisable.
  2. Women who are pregnant or breastfeeding.
  3. Past history of nonresponsive to TNF (tumor necrosis factor) blocking agents or other biologic treatment.
  4. Chronic antibiotic therapy, if the investigator considers this may affect the safety of the subject or the assessment of the study results.
  5. Any previous or current serious medical conditions that, in the opinion of the investigator, constitute a for the study treatment, as:
  6. Administration of vaccines:

    1. Subjects who have received a within 3 months prior to the randomization Visit (for example, varicella-zoster, oral polio, rabies, yellow fever vaccines.)
    2. Subjects who have received the BCG (bacillus Calmette-Guerin) vaccine within 12 months before the Selection.
  7. Presence of :

    a. At the time of the inclusion i. Active infections. ii. Fever (≥38 °C) or active, chronic or recurrent infections that require treatment with antibiotics, antiviral, or anti-fungal medications within 4 weeks prior to Screening Visit, or history of frequent recurrent infections unacceptable to the investigator's opinion.

    iii. Non-healing infected skin ulcers. b. In the previous time: i. Background of recurrent bacterial, viral, fungal (excluding superficial infections or nail bed mycosis), mycobacterial or other severe infections within the last month previous to selection.

    ii. Hospitalization for infection or Subjects who have received antibiotics intravenously within the last month or orally within the last 2 weeks.

    iii. Subjects with herpes zoster in the last 2 months.

  8. Past history of drug or alcohol abuse within the last year prior to the Screening Visit.
  9. Known to the study drug or history of severe allergy or anaphylactic reaction to monoclonal antibodies or fusion or human proteins.
  10. Any condition that, in the investigator opinion, would not allow compliance with the guidelines of the study by the patient.
  11. The subject presents absolute contraindications for the use of etanercept, according to the prospectus
  12. Presence of significant laboratory abnormalities in the screening visit.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Active comparator
    Enbrel®

    Enbrel® 50 mg injectable solution in autoinjector SureClick® contains: 50 mg etanercept and excipients/Once a week Methotrexate 15 to 25 mg /Once a week

    Biological: Etanercept · Drug: Methotrexate

  • Experimental
    Enerceptan®.

    Enerceptan®. Injectable Solution in prefilled syringes Source: GEMABIOTECH S. A. Formulation per unit: 1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg /Once a week

    Biological: Etanercept · Drug: Methotrexate

Interventions

06

What researchers measure

Primary outcomes

  1. ACR (American College of Rheumatology) 20

    The percentage of patients who achieved ACR20 at Week 32 is the primary end point. Signs and symptoms are assessed with a composite rating scale of the ACR (American College of Rheumatology) that includes 7 variables: * Tender Joints Count * Swollen Joints Count * Levels of an acute phase reactant (CRP level) * Patient's assessment of pain * Patient's global assessment of disease activity * Physician's global assessment of disease activity * Patient's assessment of physical function

    Time frame: 32 weeks of treatment

Secondary outcomes

  1. ACR (American College of Rheumatology) 50

    ACR50 is defined as the percentage of patients who achieve at least 50% improvement in both tender joint count and swollen joint count, and at least 50% improvement in at least 3 of the 5 other assessments.

    Time frame: 32 weeks of treatment

  2. ACR (American College of Rheumatology) 70

    ACR70 is defined as the percentage of patients who achieve at least 70% improvement in both tender joint counts and swollen joint counts and at least 70% improvement in at least 3 of the 5 other assessments of the ACR

    Time frame: 32 weeks of treatment

  3. DAS (Disease activity state)

    It will be measured using the DAS (Disease activity state) 28. DAS28 is a composite score that includes 4 variables: * Tender Joints Count (based on 28 joints) * Swollen Joints Count (based on 28 joints) * Patient's global assessment of disease activity * Marker of inflammation: C REACTIVE PROTEIN

    Time frame: 32 weeks of treatment

  4. EULAR (European League Against Rheumatism) response criteria

    * Good response = Percentage of patients with an improvement of \>1.2 and a present DAS score ≤3.2. * Moderate response = Percentage of patients with either an improvement of \>0.6 to ≤1.2 and a present score ≤5.1, or an improvement \>1.2 and a present score \>3.2 * Non response = Percentage of patients with either an improvement of ≤0.6 or an improvement \>0.6 to ≤1.2 and a present score \>5.1

    Time frame: 32 weeks of treatment

  5. Time to onset of benefit

    ACR20, will be also analyzed at every clinic visit to allow an analysis of the time to onset of benefit for achievement of ACR

    Time frame: 32 weeks of treatment

  6. Change in modified van der Heijde Sharp score

    • The Sharp method is a composite X-ray scoring system used to assess structural (joint) disease progression in rheumatoid arthritis. The method evaluates both joint erosions (JE) and joint space narrowing (JSN) in bilateral hand and foot joints

    Time frame: 32 weeks of treatment

  7. Physical function

    • Improvement in physical function is assessed by change from baseline in HAQ (Health Assessment Questionnaire) at Week 32.The HAQ-DI (disability index) is composed of 8 categories as follows: dressing and grooming, arising, eating, walking, hygiene, reach, grip and activities, for which there are at least 2 questions by category. The patient will be asked to score how difficult he/she feels it is to perform such activities using a 0 to 3 scoring (0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do). If the patient is using assistance for any of these activities, scoring may be adjusted. For each category, the highest score given for one of the question is attributed to the category. The total score is the sum of all categories' scores divided by the number of answered categories (at least 3 categories should be answered)

    Time frame: 32 weeks of treatment

  8. Functional Assessment of Chronic Illness Therapy Fatigue scale (FACIT-Fatigue)

    The FACIT-Fatigue is a 13-item questionnaire rated 0 to 4. The patient will be asked to answer to 13 questions rated 0 to 4 (0=not at all, 1=a little bit, 2=some what, 3=quite a bit, 4=very much

    Time frame: 32 weeks of treatment

  9. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).

    Infections, hematological disorders, neurologic disorders and malignancies. Adverse Drug Reactions. Incidence, seriousness and severity. Serum Hematological and chemistry values.Local Adverse Drug Reactions

    Time frame: 32 weeks of treatment

  10. Steady state concentration

    Etanercept concentration measure

    Time frame: At week 16 and 32

  11. Immunogenicity

    Antibodies anti-Etanercept measure

    Time frame: At week 16 and 32

07

Study locations

1 site
  • Instituto Medico CER
    Bs As, Argentina
08

References and documents

Publications

  • Strusberg I, Mysler E, Citera G, Siri D, de Los Angeles Correa M, Lazaro MA, Pardo Hidalgo R, Spindler A, Tate P, Venarotti H, Velasco Zamora J, Klimovsky E, Federico A, Scheines E, Gonzalez E, Cordeiro L, Lago N. Efficacy, Safety, and Immunogenicity of Biosimilar Etanercept (Enerceptan) Versus Its Original Form in Combination With Methotrexate in Patients With Rheumatoid Arthritis: A Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study. J Clin Rheumatol. 2021 Sep 1;27(6S):S173-S179. doi: 10.1097/RHU.0000000000001616. PubMed 33337815 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Mar 2017 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2016
First posted
Nov 6, 2017
Start
Feb 2016
Primary completionActual
Mar 2017
CompletionActual
Sep 2017
Last update
Nov 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03332719
Lead sponsor
Gema Biotech S.A.
Collaborators
QUID Quality in Drugs and Devices Latin American Consulting SRL
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Feb 2016
Primary completion
Mar 2017
Completion
Sep 2017
Last update
Nov 6, 2017

Study contacts

Jorge Velasco, MD
principal investigator · Instituto Médico CER
Maria de los Angeles Correa, MD
principal investigator · PAMPA
Maria Alicia Lazaro, MD
principal investigator · IARI
Rodolfo Pardo Hidalgo, MD
principal investigator · CER San Juan
Daniel Siri, MD
principal investigator · CAICI
Alberto Jorge Spindler, MD
principal investigator · Centro Médico Privado de Reumatología
Ingrid Strusberg, MD
principal investigator · Centro Reumatologico Strusberg
Patricio Tate, MD
principal investigator · OMI
Horacio Oscar Venarotti, MD
principal investigator · Atención Integral en Reumatología

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion